TL;DR
This study investigated the real-world impact of paclitaxel-coated balloons (DCBs) on patient mortality, finding that the total cumulative dosage of paclitaxel, not just the frequency of use, is a significant predictor of death. This suggests a potential dose-response relationship that warrants cautious use of DCBs, especially in high-risk patients.
What Problem Does This Paper Address?
Drug-coated balloons (DCBs) are widely used to improve the patency of blood vessels, particularly in the femoropopliteal arteries, by delivering paclitaxel to prevent restenosis. However, concerns have been raised about a potential increase in long-term mortality associated with these devices, stemming from systematic reviews and FDA reports. While some studies have found no such link, the debate continues. A key unanswered question is whether there's a dose-response relationship – meaning, does a higher cumulative exposure to paclitaxel lead to a greater risk of mortality? This paper aims to address this by analyzing real-world patient data to explore the correlation between paclitaxel dosage and frequency of use with mortality outcomes.
Methods
The researchers conducted a retrospective analysis of 225 patients who underwent DCB angioplasty for femoropopliteal atherosclerotic lesions between February 2013 and December 2018. They meticulously collected patient-level data, including demographics, comorbidities (like cancer status), lesion characteristics, and crucially, the initial and total cumulative dosages of paclitaxel administered, as well as the frequency of DCB use over time.
To determine the predictors of all-cause mortality, they employed time-dependent Cox regression analysis. This statistical method is well-suited for analyzing survival data and accounts for factors that change over time, such as paclitaxel exposure. They considered a comprehensive set of variables, including patient demographics, comorbidities, lesion characteristics, and paclitaxel exposure data. To pinpoint the optimal paclitaxel dosage threshold for predicting mortality, they used a minimum p-value approach.
Datasets
The study utilized a real-world, independent, patient-level dataset collected from Samsung Medical Center. This dataset comprised 225 patients who underwent DCB angioplasty. The data was gathered retrospectively from February 2013 to December 2018 for treatment and extended to July 2020 for mortality follow-up. Data sources included the National Health Insurance Service, telephone surveys, and medical record reviews, including death certificates.
Key Insights and Ideas
- Cumulative Dose Matters Most: The study's most significant finding is that the total cumulative dosage of paclitaxel, rather than just the number of times a DCB was used, emerged as a significant predictor of mortality. This highlights the importance of considering the overall drug burden on the patient.
- Dose-Response Hypothesis Supported: The identification of a dose-response relationship, even if the statistical significance was borderline for the overall population, provides crucial evidence supporting the hypothesis that higher paclitaxel exposure could be linked to increased mortality.
- Critical Limb Ischemia (CLI) Patients at Higher Risk: The analysis revealed that patients with Critical Limb Ischemia (CLI) were particularly vulnerable. The total paclitaxel dosage was a significant predictor of mortality specifically within this high-risk subgroup.
- Age and CLI are Independent Risk Factors: Beyond paclitaxel dosage, advanced age and the presence of CLI were independently identified as strong predictors of mortality, underscoring the complex interplay of patient factors and treatment.
- Frequency of Use Less Predictive: Interestingly, while the frequency of DCB use was significant in univariable analysis, it did not remain a significant predictor of mortality in the multivariable model, suggesting that the amount of drug delivered is more critical than the number of treatments.
Key Results
- Out of 225 patients analyzed, 56 (24.9%) died during a mean follow-up of 35 months.
- Multivariable Cox regression identified age (HR 1.057, p=0.0032), critical limb ischemia (CLI) (HR 4.135, p<0.0001), and total dosage of paclitaxel (mg) (HR 1.040, p=0.0210) as independent predictors of all-cause mortality.
- In the CLI subgroup, the total dosage of paclitaxel (mg) remained a significant predictor of mortality (HR 1.046, p=0.0198).
- The estimated cut-off value for total cumulative paclitaxel dosage predicting mortality was 12 mg.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective, Single-Center Design: This limits the generalizability of the findings, as it reflects the practices and patient population of one institution.
- Small Sample Size: While 225 patients is a reasonable number for a real-world study, the statistical power to detect subtle dose-response relationships or interactions might be limited, especially for specific subgroups or cut-off values.
- Inability to Assess Treatment Changes: The study couldn't fully account for changes in medical management during the follow-up period.
- No Direct Comparison to Uncoated Balloons: The study did not directly compare mortality rates between patients treated with DCBs and those treated with uncoated balloons, which would provide a clearer picture of the DCB-specific risk.
- Lack of Definitive Mechanism: The study identifies a correlation but cannot definitively prove the physiological mechanism by which paclitaxel might cause long-term mortality.
Future work suggested includes:
- Prospective, Comparative Studies: The authors emphasize the need for prospective, comparative studies to definitively establish mortality differences between DCB and uncoated balloon treatments.
- Larger Sample Sizes: Larger studies are needed to confirm the dose-response relationship and explore potential causal mechanisms.
- Cautious Use and Alternative Options: Given the findings, the authors recommend cautious use of DCBs, particularly in CLI patients, and suggest considering alternative treatments like bypass surgery for repeated DCB use.
Summary updated